



## COSMOGRAPHICS ANNOUNCES ACQUISITION OF AT-GC BIOPHARM'S ELECTRONIC EYE TECHNOLOGY

Mumbai, India, And Baltimore, MD., USA July 12 /PRNewswire/ -- Cosmographics, a specialty biochemical company focused on intelligent manufacturing of biopharmaceuticals, today announced the acquisition of a novel Electronic Eye technology for use in biopharmaceutical manufacturing. Cosmographics acquired the proprietary technology, known as Electronic Eye, from AT-GC BioPharm in for an undisclosed upfront sum, plus future milestone payments and royalties on product sales. Scientifically, the Electronic Eye approach mirrors that of Cosmographics existing intelligent manufacturing technology, by utilizing innovative biosensors to monitor fermentation processes for optimal production of biopharmaceuticals.

"The acquisition of the AT-GC BioPharm's Electronic Eye technology provides us with a unique opportunity to expand our manufacturing capabilities of next generation therapeutic products," said Sunil Majmundar, Cosmographics CEO. "I am delighted that we have completed this acquisition so soon after establishing biopharmaceuticals manufacturing earlier this year, and believe it will prove an important step in building a broad, world-class intelligent bio-manufacturing company."

### About Electronic Eye technology

AT-GC has developed a self-monitoring closed-loop technology that uses non-invasive and non-destructive near infrared and acousto-optical sensors to regulate the manufacturing process in real-time. The technology platform addresses one of the most painful aspects of manufacturing- the capacity crunch-without significant capital investments. Arkesh Mehta, CEO of AT-GC BioPharm is confident that the non-invasive and non-destructive real time monitoring technology will allow Cosmographics to manufacture quality assured products for their customers.

The Electronic Eye platform provides for continuous monitoring of complex processes without having to physically sample and measure individual components. In proof of concept studies real time monitoring has shown improvement in manufacturing processes of up to four fold.

"The biopharmaceuticals space continues to be plagued by manufacturing inconsistencies and inefficiencies that would be unacceptable in other industries," commented Tracy Tucker, Director of R & D, AT-GC BioPharm. "The Electronic Eye technology is the only technology that we have seen that provides for better than just incremental improvements in biologics manufacture. We are thrilled to work with Cosmographics and be the first CMO to offer this exciting technology to customers in South East Asia."

About AT-GC BioPharm: (<http://www.biopharm.at-gc.com/>)

AT-GC BioPharm is a biopharmaceutical process innovation company. AT-GC has developed a proprietary Intelligent Manufacturing Platform for biopharmaceuticals. AT-GC technology platform is a self monitoring closed loop technology that uses non-invasive and non-destructive near infrared and acousto-optical sensors to regulate the manufacturing process in real-time. The technology platform addresses one of the most painful aspects of bio- manufacturing-the capacity crunch-without significant capital investments. The total market for the biologics manufacturing is expected to be \$30-40 billion. The process development segment is expected to be \$10-15 billion, with more than 50% outsourcing. The technology platform is global regulatory agency (FDA, EMEA and ICH) compliant, with excellent quality assurance and electronic submission components built-in. The management has more than 100 years of combined Brain to Bank management experience in biopharmaceutical industry.

For more information please visit <http://www.at-gc.com/>.

Avanti Therapeutics

CONTACT:

Contacts: Arkesh Mehta, CEO, Avanti Therapeutics, Tel: 1-301-540-5474; Jenny Smith, Communications, [jenny@ar-gc.com](mailto:jenny@ar-gc.com).

Cosmographics

CONTACT:

Sunil Majmundar, Tel: 91, 222-516-9310 and 91 9820763136. [Cosmographics@yahoo.com](mailto:Cosmographics@yahoo.com).